Keratoacanthoma - Keratoakanthom
☆ In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
Typicam Keratoakanthom (Keratoacanthoma)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) tumor cutis creber notus est ob eius celerem incrementum ac facultatem ad remissionem spontanee. Plerumque in senioribus, albis hominibus cum historia solis damni occurrit. Chirurgica remissio per excisionem vel per micrographiam Mohs solita est; variae optiones therapiae praesto sunt.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) est tumor humilis gradus, qui in quibusdam glandulis cutis incipit et sub microscopio similis est squamous cell carcinoma (SCC). Diuturna disputatio est de an KA ponenda sit forma incursionis SCC.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) secundum genus cancri frequentissimum est in hominibus, praesertim inter homines vetustiores. Chirurgia typice tractat cSCC, sed pro quibusdam aegris, qui chirurgiam subire non possunt vel nolunt, aliae optiones, sicut curationes intralesionales, considerari possunt. Traditionales curationes intralesionales, ut methotrexate vel 5‑fluorouracil, adhibentur, sed in recentibus investigationibus novae accessiones, ut immunoterapia intralesionalis et virotherapia oncolytica, explorantur. In hoc videbimus varias curationes intralesionales pro cSCC, a methodis classicis usque ad consilia incisionis et optiones emergentes.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Sub microscopio, keratoakanthom (Keratoacanthoma) carcinoma squamoso valde propinqua est. Cum nonnulli pathologi keratoakanthom (Keratoacanthoma) quasi distinctam entitatem, non malignam, indicent, circa 6 % casuum histologicorum keratoakanthom (Keratoacanthoma) in carcinomata cellulae squamae invasiva et metastatica progrediunt.
○ Diagnosis et curatio
#Dermoscopy
#Skin biopsy